I show you how I was taught to do muscle testing. I LOVE my PURE, no filler added, organic, NON-GMO, 30 day, money back guaranteed, full spectrum CBD oil made from two ingredients (Hemp oil and CBD oil, both from the same plant). The peppermint and cinnamon flavored ones also contain a natural flavor. It comes in 500 and 750. It is doing wonders, not only for me, but for my parents and friends, too.
To get started on your Hemp CBD oil journey, go to http://2purecbdoil.com/
Optic neuritis (ON) is characterized by inflammation of the optic nerve with acute loss of vision in one eye. It is among the initial manifestations of multiple sclerosis (MS) and occurs secondary to demyelination. Most reported cases are associated with MS; however, it may occur in isolation.
Nerve affected by multiple sclerosis. Image Credit: Designua / Shutterstock
ON has been observed in approximately 20% of MS patients as an initial manifestation and in almost 50% of patients during the course of the disease. The Optic Neuritis Treatment Trial (ONTT) showed that after a 15-year follow-up period, almost half of ON patients had converted to clinically definite MS. Looking at the risk of conversion to MS, it is clear that prompt diagnosis and effective management of the affected patients is necessary.
ON causes painful visual loss that mainly afflicts young adults, especially females is associated with a wide variety of symptoms, and.
Symptoms of Optic Neuritis
ON is characterized by symptoms such as visual defects, pain in the periorbital region, and problems with color vision. Vision defects may be mild or severe, such as loss of light perception, and are usually associated with prior pain. Periocular or retro-ocular pain accompanying eye movements is common among these patients. Defects in the visual field are observed in ON and may include focal defects or diffuse defects.
Diagnosis and Predicting Conversion to MS
ON is the most common initial manifestation of MS; however, it is difficult to predict the long-term prognosis. There are some important factors which may help predict the risk of conversion to MS and help with the long-term management of the disease. Factors such as patient demographics, genetics, neurological, and fundus findings are all important in predicting the risk.
Neuroimaging using magnetic resonance imaging (MRI) can provide valuable insights in this regard. MRI of the brain, orbits, and spinal cord can be used for diagnosis, and these lesions in particular can be strong indicators of MS risk. The probability of developing MS increases with the number of lesions. The majority of patients with ON show abnormalities in white-matter T2 signal in an MRI scan.
The McDonald criteria comprise a sensitive and accurate diagnostic tool used to predict the risk of conversion to MS. These have been updated to provide defined fixed criteria for DIS (dissemination in space) and DIT (dissemination in time) of CNS lesions, and assists with the detection of MS after a single episode of neurologic symptoms. McDonald criteria also aid in the differential diagnosis by excluding other diseases.
Cerebrospinal fluid (CSF) analysis may also help in diagnosis; oligoclonal banding (OB) and immunoglobulin G (IgG) index are the most useful predictors of MS.
The evoked potentials test is yet another extremely sensitive diagnostic tool used to predict disease risk even in asymptomatic or silent cases. Visual evoked potential (VEP) testing measures the electrical activity of the brain in response to a visual stimulus and detects the speed of propagation of the nerve impulse. Thus it can detect lesions even before the development of symptoms.
Optical coherence tomography (OCT) is a recently developed and safe technique to determine the thickness of retinal nerve fibers and retinal tissues. The OCT test can determine the thinning of the nerve fiber layers in patients with prior ON. This test is useful to quantify the loss of optic nerve axons and hence helps in the assessment of disease progression.
The treatment strategy in ON usually involves intravenous corticosteroid therapy such as methylprednisolone. Intravenous dexamethasone is also an option for patients with acute ON. Its ease of availability and low cost makes it an attractive alternative to methylprednisolone. However, even though steroids have been found to hasten recovery of vision initially, they have no effects on the final visual outcome.
Immunomodulator and intravenous immunoglobulin therapy may be useful in patients with one or more lesions, however, the potential risk to benefit ratio should be assessed before starting therapy.
Several studies have demonstrated useful insights regarding the clinical features of ON associated with MS; however, more understanding of the factors responsible for disease severity and better diagnostic tools are still required. This will help prevent inaccurate treatments and result in the adoption of the appropriate treatment strategy.
A timeless self care ritual for body and mind: light some candles and step into a hot tub. Nothing’s better—until you add Ashley Spierer’s organic CBD soak. CBD (hers is full spectrum, from hemp), is thought to offer relief from pain, inflammation, anxiety, and depression. Mixed with arnica and Epsom salt—each a powerful, natural ingredient on its own—your bath’s benefits are raised to the 100th power. (We’re not mathematicians, but that feels right.) Your nose gets a treat, too: Ashley’s forest-fresh blend of essential oils gives you the feeling of being in a Pacific Northwest wonderland. Emerge feeling calm and refreshed, floating on a cloud of canna-bliss. Vegan, Leaping Bunny Certified Cruelty Free. Handmade in Seattle, Washington.
Green Thumb Industries (CSE:GTII) (OTCQX:GTBIF) recently acquired Las Vegas-based Integral Associates for $290 million, the largest acquisition of its kind in Nevada’s cannabis industry to date. The deal will close sometime during the first half of 2019.
Integral Associates is best known for its Essence retail brand which operates three locations across the Las Vegas Valley. Business Insider ranked Essence as one of the best dispensaries in Nevada, and it’s been recognized by Leafly and High Times as well. In total now, Green Thumb Industries owns eight facilities and 60 retail licenses across eight states.
“We are thrilled to expand GTI’s production, distribution and retail footprint in one of the most popular tourist destinations in the world,” said Ben Kovler, GTI Founder and Chief Executive Officer in a statement. “Integral Associates are exceptional operators—they have a highly admired and respected business comprised of two world-class cultivation and processing facilities, multiple award-winning products, strong wholesale distribution, three impressive retail dispensary locations with significant retail market share and healthy EBITDA.”
Along with the dispensaries, GTI also acquired Desert Grown Farms and Cannabiotix NV, two cultivation facilities that add up to just shy of 100,000-square-feet. Desert Grown Farms also has a genetics library that includes over 100 strains of cannabis. Both facilities possess award-winning cannabis strains, including 25 strains that are unique to the brand.
As part of the acquisition, two of Integral Associates’ founders — Alex and Armen Yemenidjian — will join GTI’s leadership team. Armen will take on the role of President for the senior leadership team, and his brother Alex will be joining the Board of Directors as a member of the audit committee.
“We are excited to welcome Armen Yemenidjian to our senior leadership team, where he will serve as president,” continued Kovler in a statement. “Armen’s wealth of experience in building and growing an outstanding company will be a tremendous asset to our organization. We are also pleased to announce that Alex Yemenidjian will be joining our Board of Directors, and we look forward to leveraging his vast and varied experience and success.”
Alex comes with years of experience as Chairman of the Board for the Tropicana Casino and Metro-Goldwyn-Mayer, Inc. GTI CEO Ben Kovler welcomed the brothers in a statement.
The economics of cannabis in Nevada
Green Thumb Industries owns and operates both medical and recreational dispensaries in various markets, including the popular RISE recreational dispensaries — two of which are in Nevada. At the deal’s closing, GTI will become the largest dispensary operator in Nevada.
However, they’re not the only company to recognize the potential of Nevada’s cannabis market, most of which is based in Las Vegas. With over 42 million tourists from around the world visiting last year, the state saw more than $500 million in medicinal and recreational cannabis sales in its first fiscal year which generated just under $70 million in tax revenue, according to a report put out by the Nevada Dispensary Association.
Even better was the fact that those numbers were 60 percent higher than Nevada’s original projection, with $20 million more in tax revenue. According to local Las Vegas News 3, the Nevada Department of Taxation put the extra $42.5 million into the state’s rainy day fund after giving $27.5 million to the public schools.
According to the Nevada Dispensary Association’s report, the state could easily see $1 billion in tax revenue over the next seven years. Numbers could jump exponentially if the federal law against marijuana were to be lifted. As it stands right now, the state is still combating the black market, with many dispensary owners telling local papers that black market dealers are their top competition.
“The industry is growing very, very rapidly,” NDA President Andrew Jolley told Local News 3 last month. “The black market is still very much alive in our state. We would like to see that demand for cannabis products channeled into the regulated, legal framework, where we have high quality tested products that pay taxes and generate revenue for the state.”
The largest cannabis market in the United States
Despite issues with illegal sales, the economic report surmises that Nevada could be the largest marijuana marketplace in the United States within five years, presenting a potentially unique opportunity for investors. Unlike other North American cannabis markets, such as Canada or Oregon, Nevada does not have a supply issue. Instead, their problems are with pricing.
Joe Brezny, the director of political operations with Nevada’s Carrara Nevada lobbying group, addressed the issue in June.
“If you look at the markets that are established, there’s going to be a little bit of a seesaw effect here because we’re only hitting about a third of the black market,” Brezny said in an interview with the Las Vegas Review-Journal. “With a bunch of people building now, that’s going to cause prices to drop, which will bring a bunch of new people in the market, which will cause prices to go back up.”
“And then more capacity will come online, and it will drop again,” he continued.
According to his interview with the Journal, Brezny sees prices falling pretty steeply over the next two or three years, from $340 per ounce at current prices to anywhere from $90 to $150.
Header Image: Essence Dispensary/ Source: Green Thumb Industries
https://i1.wp.com/elocure.com/wp-content/uploads/2018/11/new-acquisitions-put-green-thumb-industries-forefront-nevada-cannabis-industry.jpg?fit=1500%2C844&ssl=18441500Stevehttps://elocure.com/wp-content/uploads/2018/01/cbd-oil-Cannabinoid-buy.pngSteve2018-11-20 06:24:522018-11-20 06:24:52New acquisitions put Green Thumb Industries at the forefront of Nevada's cannabis industry
Cipher Capital Lp increased Garmin Ltd (GRMN) stake by 166.47% reported in 2018Q2 SEC filing. Cipher Capital Lp acquired 9,384 shares as Garmin Ltd (GRMN)’s stock rose 9.98%. The Cipher Capital Lp holds 15,021 shares with $916,000 value, up from 5,637 last quarter. Garmin Ltd now has $12.36B valuation. The stock increased 0.40% or $0.26 during the last trading session, reaching $65.48. About 815,929 shares traded. Garmin Ltd. (NASDAQ:GRMN) has risen 31.61% since November 18, 2017 and is uptrending. It has outperformed by 15.99% the S&P500. Some Historical GRMN News: 11/04/2018 – The zūmo® 396 motorcycle navigator from Garmin® brings live features to stay connected on every ride; 13/03/2018 – NORDEA ROLLS OUT PAYMENT SOLUTION FOR FITBIT, GARMIN SMARTWATCH; 06/03/2018 – GARMIN INTERNATIONAL – FLIGHT PLANS MAY BE TRANSFERRED FROM FLTPLAN GO TO GARMIN PILOT APPLICATION FOR IOS AND ANDROID USERS; 02/05/2018 – GARMIN 1Q REV. $711M, EST. $669.0M; 15/05/2018 – Squarepoint Ops Adds Garmin, Exits IBM, Buys More Lululemon: 13F; 02/05/2018 – Garmin Sees FY18 Adj EPS $3.05; 18/04/2018 – Garmin® introduces the Edge® 130 – a compact GPS bike computer designed for use on any ride; 18/04/2018 – Garmin® hosts second Connect IQ™ Developer Summit, announces Connect IQ 3.0 with new apps from Trailforks, Yelp, iHeartRadio; 04/05/2018 – Garmin Conference Call Scheduled By Aliya Capital for May. 11; 03/05/2018 – Introducing inReach® Mini from Garmin®, a small but mighty two-way satellite communicator for any adventure
Insys Therapeutics Inc (INSY) investors sentiment increased to 1.33 in Q2 2018. It’s up 0.58, from 0.75 in 2018Q1. The ratio has increased, as 40 hedge funds increased or started new holdings, while 30 decreased and sold stock positions in Insys Therapeutics Inc. The hedge funds in our database now possess: 12.52 million shares, up from 12.41 million shares in 2018Q1. Also, the number of hedge funds holding Insys Therapeutics Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 17 Increased: 26 New Position: 14.
Orbimed Advisors Llc holds 0.3% of its portfolio in INSYS Therapeutics, Inc. for 3.51 million shares. Gam Holding Ag owns 83,940 shares or 0.02% of their US portfolio. Moreover, Tci Wealth Advisors Inc. has 0.02% invested in the company for 7,766 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. Panagora Asset Management Inc, a Massachusetts-based fund reported 185,009 shares.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $527.32 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.
More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Globenewswire.com which released: “INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets” on November 05, 2018, also Seekingalpha.com with their article: “INSYS up 6% premarket on encouraging data on opioid overdose nasal spray” published on November 01, 2018, Globenewswire.com published: “INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5” on October 22, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Globenewswire.com and their article: “Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central …” published on October 29, 2018 as well as Benzinga.com‘s news article titled: “75 Biggest Movers From Yesterday” with publication date: November 07, 2018.
The stock decreased 1.80% or $0.13 during the last trading session, reaching $7.1. About 249,013 shares traded. INSYS Therapeutics, Inc. (INSY) has declined 6.48% since November 18, 2017 and is downtrending. It has underperformed by 22.10% the S&P500. Some Historical INSY News: 14/05/2018 – U.S. and 5 States Add Their Support to Lawsuit Filed by The Employment Law Group against Insys Therapeutics; 16/03/2018 – HQGE Unveils Extensive Cannabidiol (CBD Oil) Database, Teams with Hemp, Inc. to Produce and Distribute High-Quality Customizabl; 19/04/2018 – GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT; 08/03/2018 – INSYS 4Q ADJ LOSS/SHR 61C, EST. LOSS/SHR 14C; 13/03/2018 – NULL GW PHARMACEUTICALS ANNOUNCES RECEIPT OF NOTICES OF ALLOWANCE BY THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR FIVE NEW EPIDIOLEX® (CANNABIDIOL) PATENTS; 26/03/2018 – Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model; 18/04/2018 – INSYS THERAPEUTICS TO ADVANCE RESEARCH OF DRONABINOL INHALATION; 08/05/2018 – INSYS, LUNATUS TO COMMERCIALIZE SUBSYS SPRAY IN MIDDLE EAST; 08/03/2018 – Insys Therapeutics 4Q Loss/Shr 65c; 08/05/2018 – INSYS Therapeutics Announces Exclusive License Partnership With Lunatus to Commercialize SUBSYS (Fentanyl Sublingual Spray) in the Middle East
Investors sentiment increased to 1.31 in 2018 Q2. Its up 0.52, from 0.79 in 2018Q1. It increased, as 18 investors sold GRMN shares while 108 reduced holdings. 47 funds opened positions while 118 raised stakes. 75.52 million shares or 5.99% more from 71.26 million shares in 2018Q1 were reported. Hussman Strategic Advsr reported 51,050 shares or 0.84% of all its holdings. 170 are owned by Mitsubishi Ufj Securities Holding Limited. Wolverine Asset Management Ltd Liability Corporation has invested 0.01% in Garmin Ltd. (NASDAQ:GRMN). 107 were accumulated by Huntington Commercial Bank. Prudential Public Ltd has invested 0.02% in Garmin Ltd. (NASDAQ:GRMN). 10,278 were accumulated by Natixis Advsr Ltd Partnership. Omers Administration has invested 0.03% in Garmin Ltd. (NASDAQ:GRMN). Moreover, Ameriprise Fincl has 0% invested in Garmin Ltd. (NASDAQ:GRMN) for 67,670 shares. Price T Rowe Associate Md owns 172,979 shares. 61,244 are held by Voloridge Investment Ltd Company. Moody Bancorp Tru Division holds 0.01% of its portfolio in Garmin Ltd. (NASDAQ:GRMN) for 4,000 shares. Bluecrest Cap Mgmt Limited holds 9,691 shares. South Texas Money has invested 1.46% in Garmin Ltd. (NASDAQ:GRMN). 9,916 are owned by World Asset Mgmt Inc. Wells Fargo Mn holds 0.01% of its portfolio in Garmin Ltd. (NASDAQ:GRMN) for 499,964 shares.
Since May 17, 2018, it had 0 buys, and 32 selling transactions for $403.09 million activity. On Wednesday, October 31 KAO MIN H sold $44.86M worth of Garmin Ltd. (NASDAQ:GRMN) or 678,401 shares. 3,884 Garmin Ltd. (NASDAQ:GRMN) shares with value of $252,460 were sold by Desbois Patrick. PEMBLE CLIFTON A sold $1.09 million worth of stock. Bartel Danny J also sold $92,397 worth of Garmin Ltd. (NASDAQ:GRMN) on Thursday, May 17. Huang Pao-Chang sold $143,023 worth of stock or 2,375 shares.
More notable recent Garmin Ltd. (NASDAQ:GRMN) news were published by: Nasdaq.com which released: “Could a Partnership Save GoPro?” on November 17, 2018, also Fool.com with their article: “Better Buy: Garmin Ltd. vs. Fitbit Inc.” published on November 04, 2018, Seekingalpha.com published: “Garmin Ltd. 2018 Q3 – Results – Earnings Call Slides” on October 31, 2018. More interesting news about Garmin Ltd. (NASDAQ:GRMN) were released by: Bizjournals.com and their article: “Garmin ranks among nation’s most reputable tech companies” published on November 08, 2018 as well as Bizjournals.com‘s news article titled: “Garmin opens warehouse and manufacturing facility at Olathe HQ [PHOTOS]” with publication date: October 24, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
https://elocure.com/wp-content/uploads/2018/01/cbd-oil-Cannabinoid-buy.png00Stevehttps://elocure.com/wp-content/uploads/2018/01/cbd-oil-Cannabinoid-buy.pngSteve2018-11-20 05:24:012018-11-20 05:24:01Cipher Capital LP Has Lifted By $563,040 Its Garmin LTD (GRMN) Holding; Insys Therapeutics Has 1.33 Sentiment
Salzhauer Michael decreased Jpmorgan Chase & Co (JPM) stake by 62.59% reported in 2018Q2 SEC filing. Salzhauer Michael sold 54,011 shares as Jpmorgan Chase & Co (JPM)’s stock rose 2.83%. The Salzhauer Michael holds 32,289 shares with $3.37M value, down from 86,300 last quarter. Jpmorgan Chase & Co now has $365.71 billion valuation. The stock decreased 0.07% or $0.08 during the last trading session, reaching $109.99. About 13.80M shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 24.41% since November 18, 2017 and is uptrending. It has outperformed by 8.79% the S&P500. Some Historical JPM News: 26/04/2018 – ANTHEM INC ANTM.N : JP MORGAN RAISES TARGET PRICE TO $287 FROM $261; 16/03/2018 – JPMORGAN CHASE & CO JPM.N : CREDIT SUISSE RAISES TARGET PRICE TO $127 FROM $125; RATING OUTPERFORM; 19/04/2018 – JPMORGAN CHASE & CO JPM.N – COMMITTING $4.5 BLN FOR REGIONAL HOME AND SMALL BUSINESS LENDING AND AFFORDABLE RENTAL HOUSING; 14/05/2018 – PayPal Presenting at JPMorgan Conference Tomorrow; 20/04/2018 – The platform was built over more than a year using Quorum, a type of open-source blockchain that JPMorgan has developed inhouse; 07/05/2018 – Dimon Hopeful Trade Tensions Won’t Derail JPMorgan’s China Plans; 27/03/2018 – LULULEMON ATHLETICA INC LULU.O : JP MORGAN RAISES TARGET PRICE TO $95 FROM $92; 09/03/2018 – JPMORGAN ECM EXECUTIVE DIRECTOR WU IS SAID TO BE LEAVING BANK; 13/04/2018 – JP Morgan Chase, Citigroup, Wells Faro and PNC all saw share prices fall; 13/04/2018 – JPMorgan Chase Sees 2018 Adjusted Expense About $63B
Orbimed Advisors Llc decreased Gw Pharmaceuticals Plc (GWPH) stake by 71.62% reported in 2018Q2 SEC filing. Orbimed Advisors Llc sold 53,000 shares as Gw Pharmaceuticals Plc (GWPH)’s stock declined 7.24%. The Orbimed Advisors Llc holds 21,000 shares with $2.93M value, down from 74,000 last quarter. Gw Pharmaceuticals Plc now has $4.28B valuation. The stock increased 1.50% or $1.96 during the last trading session, reaching $132.3. About 408,176 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 29.17% since November 18, 2017 and is uptrending. It has outperformed by 13.55% the S&P500. Some Historical GWPH News: 19/04/2018 – The medication, which is manufactured by GW Pharmaceuticals, is used in the treatment of seizures associated with childhood epilepsy; 19/04/2018 – GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now $GWPH; 19/04/2018 – I can’t recall ever seeing such a complete lineup signaling an FDA OK. Insider recommendation saying approve it, unanimous panel support, commitment from regulators to accelerate, no hint of hesitation. It is remarkable; 19/04/2018 – Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet; 16/05/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a P; 16/03/2018 – HQGE Unveils Extensive Cannabidiol (CBD Oil) Database, Teams with Hemp, Inc. to Produce and Distribute High-Quality Customizabl; 19/04/2018 – GW PHARMACEUTICALS PLC – PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018; 17/04/2018 – GW cannabis-derived epilepsy drug gets positive FDA staff review; 16/05/2018 – Cannabidiol Significantly Reduces Seizures in Patients with Severe Form of Epilepsy; 13/03/2018 – GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents
Analysts await GW Pharmaceuticals plc (NASDAQ:GWPH) to report earnings on December, 3. They expect $-2.39 EPS, down 9.63% or $0.21 from last year’s $-2.18 per share. After $-1.26 actual EPS reported by GW Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 89.68% negative EPS growth.
Among 6 analysts covering GW Pharma (NASDAQ:GWPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharma had 7 analyst reports since June 25, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, June 26 by Bank of America. Morgan Stanley maintained it with “Overweight” rating and $197 target in Friday, September 7 report. The rating was initiated by Goldman Sachs with “Buy” on Tuesday, June 26. As per Thursday, October 11, the company rating was maintained by Morgan Stanley. Cantor Fitzgerald maintained it with “Buy” rating and $23500 target in Monday, June 25 report.
More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Benzinga.com which released: “4 Reasons Why Leerink Is Bullish On GW Pharma” on November 14, 2018, also Seekingalpha.com with their article: “Leerink sees 34% upside in Allergan in premarket analyst action” published on November 13, 2018, Nasdaq.com published: “Why GW Pharmaceuticals Stock Dropped 20% in October” on November 10, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Benzinga.com and their article: “Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week” published on November 17, 2018 as well as Fool.com‘s news article titled: “Better Buy: GW Pharmaceuticals PLC vs. 22nd Century Group Inc.” with publication date: October 21, 2018.
Orbimed Advisors Llc increased Teleflex Inc (NYSE:TFX) stake by 73,400 shares to 190,400 valued at $51.07 million in 2018Q2. It also upped Dentsply Sirona Inc stake by 2.17 million shares and now owns 2.39 million shares. Deciphera Pharmaceuticals In was raised too.
Among 4 analysts covering JPMorgan Chase (NYSE:JPM), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. JPMorgan Chase had 4 analyst reports since July 16, 2018 according to SRatingsIntel. The firm earned “Market Perform” rating on Monday, July 16 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, July 19 by DZ Bank. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Buy” rating by Bank of America on Monday, September 17. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Neutral” rating given on Wednesday, September 26 by Citigroup.
More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: Fool.com which released: “Why Did Berkshire Hathaway Buy JPMorgan Chase Stock?” on November 18, 2018, also Investorplace.com with their article: “5 Top Stock Trades for Friday: JPMorgan, JC Penney and Walmart” published on November 15, 2018, Fool.com published: “3 Top Bank Stocks to Buy in November” on November 18, 2018. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: Streetinsider.com and their article: “Warren Buffett’s Berkshire Enters JPMorgan (JPM), Oracle (ORCL), Adds to (AAPL) (more…)” published on November 14, 2018 as well as Fool.com‘s news article titled: “Top Stocks Warren Buffett Just Bought” with publication date: November 16, 2018.
Investors sentiment increased to 0.99 in Q2 2018. Its up 0.18, from 0.81 in 2018Q1. It is positive, as 51 investors sold JPM shares while 741 reduced holdings. 112 funds opened positions while 669 raised stakes. 2.34 billion shares or 2.08% less from 2.39 billion shares in 2018Q1 were reported. 904,603 are owned by Bradley Foster And Sargent Inc Ct. Terril Brothers Incorporated holds 48,757 shares or 1.56% of its portfolio. Selway Asset has 3.27% invested in JPMorgan Chase & Co. (NYSE:JPM). Eos Mngmt Lp stated it has 0.65% in JPMorgan Chase & Co. (NYSE:JPM). Vaughan Nelson Management LP holds 15,245 shares or 0.02% of its portfolio. Hollow Brook Wealth Mgmt holds 0.74% or 9,031 shares in its portfolio. Cetera Advsr Ltd Liability Company reported 63,502 shares. Cooke & Bieler LP holds 1.7% or 908,933 shares in its portfolio. Fil Ltd holds 0.73% or 4.64M shares. Meristem Limited Liability Partnership holds 6,319 shares or 0.23% of its portfolio. Endurance Wealth Inc holds 2.23% or 129,872 shares in its portfolio. Hall Laurie J Trustee has 9,842 shares for 0.59% of their portfolio. Reinhart Ptnrs Inc reported 5,950 shares stake. Bourgeon Cap Management Ltd holds 73,958 shares. Round Table Serv Limited Liability Corp invested 0.34% in JPMorgan Chase & Co. (NYSE:JPM).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
https://elocure.com/wp-content/uploads/2018/01/cbd-oil-Cannabinoid-buy.png00Stevehttps://elocure.com/wp-content/uploads/2018/01/cbd-oil-Cannabinoid-buy.pngSteve2018-11-20 03:22:082018-11-20 03:22:08Orbimed Advisors Has Trimmed By $7.37 Million Its Gw Pharmaceuticals Plc (GWPH) Position; Salzhauer Michael Trimmed Jpmorgan Chase & Co (JPM) Stake By $5.62 Million
International Hemp Seed Oil Market report Insights, the research report presents a complete assessment of Hemp Seed Oil industry’s new upgrades, censorious trends, current Hemp Seed Oil market pilots, challenges, and standardization and technical domain. The Hemp Seed Oil report additionally introduces forecasts for Hemp Seed Oil market for the period 2018 to 2025. Hemp Seed Oil research aims to define, categorize, and estimate the size of Hemp Seed Oil market depending upon the business profile, Hemp Seed Oil product type, end-user, and top geographical regions.
This Hemp Seed Oil research report uses SWOT and Porter’s Five Forces scrutiny to spot the key players in the Hemp Seed Oil market. The report entitled Global Hemp Seed Oil Market 2018 is categorized into many important segments, along with Hemp Seed Oil production, consumption, and proceedings. The most important areas of Hemp Seed Oil market comprised are USA, Europe, China, Japan, South East Asia, India, Central & South America.
The report inspects the Hemp Seed Oil market overview, presenting the Hemp Seed Oil industry Definition, Specification, and Categorization. The report contains the Hemp Seed Oil market size, market earnings, evolution opportunities and evaluation in forthcoming years. The report on Hemp Seed Oil market also provides the Hemp Seed Oil production cost framework analysis, Hemp Seed Oil industry chain framework, raw materials, suppliers, and Hemp Seed Oil process analysis. Furthermore, the report classifies the Hemp Seed Oil market on the basis of elementary parameters and analyzes the Hemp Seed Oil market position, market perspective and Hemp Seed Oil industry top participants in the global market.
Key Manufacturers of Global Hemp Seed Oil Market by CAGR Analysis:
Global Hemp Seed Oil Market 2018 Answers the following Key Questions.
What will be the Hemp Seed Oil market size and expansion rate in 2025?
Who are the key producers of Hemp Seed Oil and Where they lie on a global scale?
What are the Hemp Seed Oil market kinetics and industry perspectives?
Who will be the target audience of Hemp Seed Oil industry?
What are the opportunities, challenges, and threats influencing the growth of Hemp Seed Oil market?
What are the main driving attributes, Hemp Seed Oil market trends, short-term, and long-term policies?
What are the opinions from professionals and their outlook on Hemp Seed Oil market and future insights?
In the end, the report includes Hemp Seed Oil market opportunities and the competitive aspect for shareholders and Hemp Seed Oil market leaders. The Hemp Seed Oil report additionally presents the research procedures, investment plans, and Hemp Seed Oil industry evolution trend analysis. Finally, with the help of complete research of Hemp Seed Oil industry for the foretell period 2018 to 2025, it can assist an individual for making business decisions that can cause achieving swift business growth in Hemp Seed Oil market across the world.
BECAUSE CBD OIL HAS NOT BEEN FDA APPROVED AS A CURE OR TREATMENT FOR ANY DISEASE, ELOCURE® DOES NOT MAKE OR SUPPORT ANY MEDICAL CLAIMS RELATED TO HEMP CBD OIL.
The statements found on this website, and others linked to from this website, have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your doctor or health practitioner before taking any supplement.